
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
What impact could the latest 2017 hypertension guidelines have on your patients? Click through our quick slideshow to find out.






